INT133228

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.88
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 2.65
Pain Relevance 0.48

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Glp1r) signal transducer activity (Glp1r)
Anatomy Link Frequency
cleavage 1
body 1
Glp1r (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 30 95.76 Very High Very High Very High
Pain 1 69.00 Quite High
anesthesia 7 25.00 Low Low
ischemia 9 5.00 Very Low Very Low Very Low
Chronic pancreatitis 6 5.00 Very Low Very Low Very Low
Inflammation 6 5.00 Very Low Very Low Very Low
alcohol 2 5.00 Very Low Very Low Very Low
nud 2 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
abdominal pain 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 168 99.32 Very High Very High Very High
Body Weight 30 99.32 Very High Very High Very High
Aging 1 93.36 High High
Cardiovascular Disease 4 86.12 High High
Myocardial Infarction 104 85.08 High High
Monsters 2 83.28 Quite High
Gastric Motility Disorder 4 82.72 Quite High
Pain 1 69.00 Quite High
Overactive Bladder 1 68.64 Quite High
Frailty 1 67.76 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
AIMS/HYPOTHESIS: The insulinotropic hormone, glucagon-like peptide-1 (GLP-1), is rapidly degraded in vivo as a result of the combination of extensive enzymatic degradation and renal extraction.
Protein_catabolism (degraded) of glucagon-like peptide-1
1) Confidence 0.88 Published 2006 Journal Diabetologia Section Abstract Doc Link 16447056 Disease Relevance 0.08 Pain Relevance 0.05
AIMS/HYPOTHESIS: The insulinotropic hormone, glucagon-like peptide-1 (GLP-1), is rapidly degraded in vivo as a result of the combination of extensive enzymatic degradation and renal extraction.
Protein_catabolism (degraded) of glucagon-like peptide-1
2) Confidence 0.78 Published 2006 Journal Diabetologia Section Abstract Doc Link 16447056 Disease Relevance 0.08 Pain Relevance 0.05
AIMS/HYPOTHESIS: The insulinotropic hormone, glucagon-like peptide-1 (GLP-1), is rapidly degraded in vivo as a result of the combination of extensive enzymatic degradation and renal extraction.
Protein_catabolism (degraded) of GLP-1
3) Confidence 0.58 Published 2006 Journal Diabetologia Section Abstract Doc Link 16447056 Disease Relevance 0.08 Pain Relevance 0.05
Therapeutic use of GLP-1 is limited by its rapid degradation by dipeptidyl peptidase-4 (DPP-4).
Protein_catabolism (degradation) of GLP-1
4) Confidence 0.56 Published 2010 Journal Cardiovasc Diabetol Section Body Doc Link PMC2996354 Disease Relevance 0.34 Pain Relevance 0.07
Because of the rapid proteolysis of GLP-1 by DPP-4, the native peptide is not suitable for therapeutic use.
Protein_catabolism (proteolysis) of GLP-1
5) Confidence 0.22 Published 2010 Journal International Journal of Clinical Practice Section Body Doc Link PMC2904489 Disease Relevance 0.47 Pain Relevance 0.13
In addition to cleavage of GLP-1, DPP-4 has been shown to cleave multiple substrates in vitro, but few of these substrates have been validated as physiological substrates in humans.
Protein_catabolism (cleavage) of GLP-1 in cleavage
6) Confidence 0.22 Published 2010 Journal International Journal of Clinical Practice Section Body Doc Link PMC2904489 Disease Relevance 0.35 Pain Relevance 0.07
The two main categories of incretin therapy currently available are: glucagon-like peptide-1 (GLP-1) analogues and inhibitors of GLP-1 degrading enzyme dipeptidyl peptidase-4 (DPP-4).
Protein_catabolism (degrading) of GLP-1
7) Confidence 0.21 Published 2008 Journal Drugs Aging Section Abstract Doc Link 18947259 Disease Relevance 0.93 Pain Relevance 0.07
-cell function and reducing body weight over a 6-week period.10 However, GLP-1 is extensively degraded in vivo,11 primarily by the enzyme dipeptidyl pepti-dase-4 (DPP-4), with such rapidity that its apparent half-life is only in the order of 1 to 2 minutes and its metabolic clearance rate exceeds the cardiac output by 2- to 3-fold,12,13 with the resultant metabolite lacking insulinotropic effects.
Protein_catabolism (degraded) of GLP-1 in body associated with body weight
8) Confidence 0.07 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2672437 Disease Relevance 0.31 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox